How to buy Travere Therapeutics stock - 09 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Travere Therapeutics stock

Own Travere Therapeutics stock in just a few minutes.


Fact checked

Travere Therapeutics, Inc is a biotechnology business based in the US. Travere Therapeutics shares (RTRX) are listed on the NASDAQ and all prices are listed in US Dollars. Travere Therapeutics employs 221 staff and has a trailing 12-month revenue of around USD$194 million.

How to buy shares in Travere Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Travere Therapeutics. Find the stock by name or ticker symbol: RTRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Travere Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Travere Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Travere Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Travere Therapeutics share price

Use our graph to track the performance of RTRX stocks over time.

Travere Therapeutics shares at a glance

Information last updated 2021-01-22.
52-week rangeUSD$8.98 - USD$25.5
50-day moving average USD$23.9526
200-day moving average USD$20.3382
Wall St. target priceUSD$31.38
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.417

Buy Travere Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Travere Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Travere Therapeutics financials

Revenue TTM USD$194 million
Gross profit TTM USD$170.1 million
Return on assets TTM -6.61%
Return on equity TTM 0%
Profit margin -40.24%
Book value $5.907
Market capitalisation USD$1.2 billion

TTM: trailing 12 months

Shorting Travere Therapeutics shares

There are currently 4.8 million Travere Therapeutics shares held short by investors – that's known as Travere Therapeutics's "short interest". This figure is 1.6% up from 4.7 million last month.

There are a few different ways that this level of interest in shorting Travere Therapeutics shares can be evaluated.

Travere Therapeutics's "short interest ratio" (SIR)

Travere Therapeutics's "short interest ratio" (SIR) is the quantity of Travere Therapeutics shares currently shorted divided by the average quantity of Travere Therapeutics shares traded daily (recently around 265521.38121547). Travere Therapeutics's SIR currently stands at 18.1. In other words for every 100,000 Travere Therapeutics shares traded daily on the market, roughly 18100 shares are currently held short.

However Travere Therapeutics's short interest can also be evaluated against the total number of Travere Therapeutics shares, or, against the total number of tradable Travere Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Travere Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Travere Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.104% of the tradable shares (for every 100,000 tradable Travere Therapeutics shares, roughly 104 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Travere Therapeutics.

Find out more about how you can short Travere Therapeutics stock.

Travere Therapeutics share dividends

We're not expecting Travere Therapeutics to pay a dividend over the next 12 months.

Have Travere Therapeutics's shares ever split?

Travere Therapeutics's shares were split on a 1:9 basis on 8 November 2011. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.

Travere Therapeutics share price volatility

Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $8.98 up to $25.5. A popular way to gauge a stock's volatility is its "beta".

RTRX.US volatility(beta: 0.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.721. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).

Travere Therapeutics overview

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences,, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site